Disclosed herein is a pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide, said compositions can further comprise an effective amount of one or more addititional active agents selected from beta2-agonists, PDE IV inhibitors and corticosteroids. Also disclosed is the use of aclidinium in free or pharmaceutically acceptable salt form in the manufacture of a medicament for treating a respiratory condition selected from asthma and chronic obstructive pulmonary disease in a patient in need of such treatment, said use comprising administering a single or twice daily metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.
